Complete Filing Data
XTL BIOPHARMACEUTICALS LTD reported Cash And Cash Equivalents of $371.0 thousand for FY2024.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean XTL BIOPHARMACEUTICALS LTD did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research And Development Expense | $98.0K | $31.0K | $30.0K | $30.0K | $38.0K | $35.0K | $38.0K | $43.0K | $443.0K | $578.0K |
| Profit Loss From Operating Activities | -$2.2M | -$765.0K | -$880.0K | -$1.0M | -$948.0K | -$842.0K | -$793.0K | -$1.2M | -$2.6M | -$3.6M |
| Profit Loss | -$1.0M | -$1.8M | -$1.3M | $435.0K | -$3.0M | -$763.0K | $3.0M | -$781.0K | -$2.5M | -$4.3M |
| General And Administrative Expense | $1.6M | $734.0K | $850.0K | $1.0M | $910.0K | $807.0K | $755.0K | $1.2M | $1.3M | $1.4M |
| Adjustments For Reconcile Profit Loss | $189.0K | $64.0K | -$19.0K | -$54.0K | $45.0K | -$50.0K | -$8.0K | $52.0K | -$220.0K | -$16.0K |
| Comprehensive Income | -$1.0M | -$1.8M | -$1.3M | $435.0K | -$1.3M | $3.0M | -$897.0K | -$2.4M | -$4.3M | |
| Profit Loss Attributable To Noncontrolling Interests | -$1.3M | $3.0M | -$781.0K | -$2.5M | -$4.3M | |||||
| Comprehensive Income Attributable To Owners Of Parent | -$1.3M | $3.0M | -$897.0K | -$2.4M | -$4.3M | |||||
| Revenue From Interest | $34.0K | $41.0K | $36.0K | $8.0K | ||||||
| Comprehensive Incomeloss For The Yeardiluted | -$1.3M | $435.0K | -$3.0M | -$763.0K | ||||||
| Other Comprehensive Income | -$116.0K | $163.0K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Cash Equivalents | $371.0K | $1.4M | $2.1M | $3.0M | $3.6M | $4.5M | $3.3M | $3.3M | $2.0M | $3.8M | $2.2M |
| Total Income And Expenses Not Involving Cash Flows | -$780.0K | $1.0M | $466.0K | -$1.4M | $2.1M | -$95.0K | -$3.8M | -$396.0K | $1.0M | $2.5M | |
| Intangible Assets Other Than Goodwill | $3.8M | $380.0K | $380.0K | $380.0K | $380.0K | $380.0K | $380.0K | $380.0K | $253.0K | $1.0M | $2.5M |
| Cash Flows From Used In Operations | -$591.0K | $1.1M | $447.0K | -$1.5M | $2.1M | -$145.0K | -$3.8M | -$344.0K | $813.0K | $2.5M | |
| Cash Flows From Used In Operating Activities | -$1.6M | -$707.0K | -$901.0K | -$1.0M | -$850.0K | -$908.0K | -$816.0K | -$1.1M | -$1.7M | -$1.9M | |
| Cash Flows From Used In Investing Activities | -$844.0K | $41.0K | $36.0K | $8.0K | $32.0K | $2.1M | $778.0K | -$2.5M | -$66.0K | -$110.0K | |
| Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities | -$591.0K | $1.1M | $447.0K | -$1.5M | $2.1M | -$145.0K | -$3.8M | -$344.0K | $813.0K | $2.5M | |
| Adjustments For Increase Decrease In Trade Account Payable | $208.0K | $19.0K | -$44.0K | -$23.0K | $22.0K | -$21.0K | -$47.0K | -$157.0K | -$106.0K | -$117.0K | |
| Revaluation Of Marketable Securities | $167.0K | -$1.0M | -$1.5M | $747.0K | $138.0K | -$574.0K | $2.8M | ||||
| Current Marketable Securities | $772.0K | $605.0K | $1.6M | $3.2M | $2.4M | $2.3M | $2.8M | $298.0K | $414.0K | ||
| Assets | $8.6M | $2.4M | $4.2M | $6.6M | $6.5M | $7.2M | $8.6M | $6.6M | $3.0M | ||
| Retained Earnings | -$159.0M | -$158.2M | -$156.5M | -$155.1M | -$155.6M | -$153.9M | -$152.6M | -$155.6M | -$154.9M | ||
| Gains From Exchange Rate Differences On Cash And Cash Equivalents | -$10.0K | -$6.0K | -$6.0K | -$3.0K | $4.0K | -$2.0K | -$2.0K | ||||
| Equity And Liabilities | $8.6M | $2.4M | $4.2M | $6.6M | $6.5M | $7.2M | $8.6M | $6.6M | $3.0M | ||
| Current Assets | $1.3M | $2.0M | $3.8M | $6.2M | $6.1M | $6.8M | $8.2M | $6.2M | $2.8M | ||
| Trade And Other Current Payables To Trade Suppliers | $790.0K | $206.0K | $187.0K | $231.0K | $254.0K | $232.0K | $253.0K | $300.0K | $17.0K | ||
| Adjustments For Decrease Increase In Other Operating Receivables | $25.0K | -$31.0K | $23.0K | -$29.0K | $39.0K | $209.0K | -$114.0K | $36.0K | |||
| Noncurrent Assets | $7.2M | $380.0K | $380.0K | $381.0K | $382.0K | $382.0K | $380.0K | $263.0K | |||
| Other Current Receivables | $110.0K | $79.0K | $102.0K | $73.0K | $112.0K | $321.0K | |||||
| Purchase Of Property Plant And Equipment Classified As Investing Activities | $54.0K | $1.0K | $2.0K | $2.0K | $2.0K | ||||||
| Other Noncurrent Financial Assets | $1.0K | $2.0K | $2.0K | ||||||||
| Increase Decrease Through Exercise Of Warrants Equity | $4.0M | $1.2M | $3.4M | ||||||||
| Cash Flows From Used In Financing Activities | $1.4M | $385.0K | $4.9M | $3.6M | |||||||
| Reclassification Adjustments On Availableforsale Financial Assets Before Tax | $116.0K | -$163.0K | |||||||||
| Losses On Disposals Of Property Plant And Equipment | $9.0K | $3.0K | $5.0K | ||||||||
| Issue Of Equity | $1.8M | $54.0K | |||||||||
| Updated Balance Of Equity Impact Of The Adoption Of Ifrs9 | $3.6M | ||||||||||
| Shortterm Deposits Not Classified As Cash Equivalents | $2.0M | $2.5M |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | -$15.0K | -$27.0K | -$10.0K | -$6.0K | -$6.0K | -$3.0K | $4.0K | -$2.0K | -$2.0K | |
| Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes | -$818.0K | $1.2M | -$38.0K | $1.3M | -$1.8M | $1.6M | ||||
| Increase Decrease In Cash And Cash Equivalents | -$1.0M | -$666.0K | -$865.0K | -$656.0K | -$818.0K | $1.2M | ||||
| Proceeds From Sales Or Maturity Of Financial Instruments Classified As Investing Activities | $204.0K | $21.0K | ||||||||
| Proceeds From Exercise Of Warrants | $1.5M | $385.0K | ||||||||
| Proceeds From Issuing Shares Warrants | 4.9M | 3.6M | ||||||||
| Proceeds From Exercise Of Options | $864.0K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Weighted Average Shares | 673.0M | 544.9M | 544.9M | 532.0M | 514.2M | 514.2M | 514.2M | 470.2M | 274.0M | 263.7M |
| Number Of Shares Issued | 881.4M | 544.9M | 544.9M | 544.9M | 514.2M | 514.21B | 514.2M | 514.2M | 274.2M | |
| Par Value Per Share | $0.10 | $0.10 | $0.10 | $0.10 | $0.10 | $0.10 | $0.10 | $0.10 | $0.10 | |
| Number Of Shares Outstanding | 881.4M | 544.9M | 544.9M | 544.9M | 514.2M | 514.21B | 514.2M | 514.2M | 274.2M | |
| Diluted Earnings Loss Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $-0.01 | $0.00 | ||||
| Basic Earnings Loss Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $-0.01 | $0.00 | ||||
| Basic And Diluted Earnings Loss Per Share | $0.00 | $0.00 | $0.01 | $0.00 | $-0.01 | $-0.02 | ||||
| Adjusted Weighted Average Shares | 704.2M | 544.9M | 544.9M | 615.5M | 514.2M | 514.2M |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Other Finance Income | $34.0K | $41.0K | $36.0K | $21.0K | $45.0K | $98.0K | $87.0K | $37.0K | $23.0K | $4.0K |
| Other Finance Cost | $112.0K | $36.0K | $27.0K | $21.0K | $17.0K | $29.0K | $35.0K | $8.0K | $7.0K | $15.0K |
| Finance Income Cost | $1.0M | -$1.0M | -$468.0K | $1.5M | -$2.0M | $79.0K | $3.8M | $465.0K | $16.0K | -$11.0K |
| Increase Decrease Through Sharebased Payment Transactions | $264.0K | $3.0K | $14.0K | $37.0K | $51.0K | $5.0K | $24.0K | $40.0K | $128.0K | $148.0K |
| Interest Received Classified As Investing Activities | $34.0K | $41.0K | $36.0K | $8.0K | $33.0K | $93.0K | $74.0K | $4.0K | ||
| Share Based Payment Transactions To Employees And Non Employees | $14.0K | $37.0K | $51.0K | $5.0K | $24.0K | $40.0K | $182.0K | $148.0K | ||
| Other Reserves | $20.0K | $20.0K | $20.0K | $20.0K | $20.0K | $20.0K | $20.0K | $20.0K | $20.0K | |
| Issued Capital | $23.1M | $14.1M | $14.1M | $14.1M | $13.2M | $13.2M | $13.2M | $13.2M | $6.6M | |
| Number Of Shares Authorised | 1.45B | 1.45B | 1.45B | 1.45B | 1.45B | 1.45T | 1.45B | 1.45B | 700.0M | |
| Revaluation Of Warrants To Purchase Ads | $1.1M | $719.0K | -$2.2M | $584.0K | $974.0K | $765.0K | ||||
| Revaluation Of Warrants To Purchase | $926.0K | $1.1M | $719.0K | $2.2M | -$584.0K | -$974.0K | -$765.0K | |||
| Interest Income | $36.0K | $8.0K | $33.0K | $93.0K | ||||||
| Depreciation Expense | $199.0K | $1.0K | $1.0K | $1.0K | ||||||
| Additional Paidin Capital | $141.3M | $146.3M | $146.3M | $146.3M | $146.0M | |||||
| Interest Received Classified As Operating Activities | -$33.0K | -$93.0K | -$87.0K | -$11.0K | ||||||
| Repayment Of Short-Term Bank Deposit | $2.0M | $6.8M | ||||||||
| Warrants | $1.1M | $2.6M | ||||||||
| Purchase Of Financial Instruments Classified As Investing Activities | $6.3M | $2.5M | $10.0K | |||||||
| Share Premium | $147.7M | $147.7M | $146.0M | $150.8M | ||||||
| Current Prepaid Expenses | $98.0K | $40.0K | $85.0K | $110.0K | ||||||
| Adjustments For Sharebased Payments | $264.0K | $3.0K | $14.0K | $37.0K | ||||||
| Adjustments For Decrease Increase In Prepaid Expenses | -$58.0K | $45.0K | $25.0K | -$31.0K | ||||||
| Additional Paid In Capital | $141.3M | $146.3M | $146.3M | $146.3M | $146.0M |
Most recent annual filing with the SEC: April 30, 2025
Data sourced from SEC EDGAR public filings as of August 6, 2026.